Method for treating puerperal purulent-catarrhal endometritis and mastitis in cows and method for its application

FIELD: veterinary science.

SUBSTANCE: the present innovation refers to medicinal preparations applied for treating puerperal purulent-catarrhal endometritis and mastitis in cows and to the method of applying the present medicinal preparations. The suggested preparation for treating puerperal purulent-catarrhal endometritis, serous, seroso-catarrhal and subclinical mastitis in cows includes 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline, trecresan (cresacin), dimethyl sulfoxide, propandiol 1.2 at the following ratio, (g/%): 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline 1.0-1.2; trecresan (cresacin) 3.0-3.18; dimethyl sulfoxide 10.0-10.5; propandiol 1.2 20-25; distilled water - the rest. The innovation deals with intra-uterine introduction of the preparation suggested at the dosage of about 70-100 ml once daily for about 4-5 d. Moreover, this preparation should be introduced into affected part of the udder at the dosage of 10 ml once daily for 3-5 d. The innovation enables to shorten the multiplicity of introduction and accelerate the terms of recovery.

EFFECT: higher efficiency of therapy.

4 cl, 2 ex, 6 tbl

 

The invention relates to veterinary medicine, namely to medicines used to treat postpartum purulent-catarrhal endometritis and mastitis in cows and usage of these medicines.

Known for the preparation and treatment of serous mastitis in cows Matilda (Veterinary legislation. - M.: Kolos, 1981. - S-328). The drug contains penicillin, streptomycin, sulfadimezin and norsulfazol, suspended in vegetable oil. The drug is administered within two to three days, twice a day every 12 hours.

There is a method of treatment mastiano E (Obstetrics, gynecology and bioengineering reproduction. - M.: Kolos, 2000. - S). The drug contains erythromycin base, sulfadimezin and oil-based. Injected into the teat of the udder in a dose of 5-10 ml twice a day for 2-3 days.

The disadvantages of these drugs and methods of their use can be attributed to the relatively low therapeutic action, the possibility of development of antibiotic resistance, long waiting periods use milk in nutritional purposes (4-6 days after the last injection of the drug), considerable labor and material costs.

Closest to the proposed and adopted for the prototype is dioxidine 1% solution and a method for its use (veterinary medicine. 2004. No. 9; EN 2228176 C2). Part of the preparation of the WMO is Yat 1,4-di-N-oxide 2,3 bis(oxymethyl) cinoxacin, preservative and water for injection. The drug is used for treatment of clinical and subclinical form of mastitis and for preventive sanitizing the teats at the beginning of the dry period. Depending on the indications the drug is injected into the teat of the udder in doses of 10 to 30 ml twice a day for 2-4 days. The drug is also used for the treatment of endometritis in the dose of 200 ml is injected into the pararectal cellular tissue.

The disadvantages of this drug and method of its use include the lack of prolonging effect, instability of the dosage form, which does not exclude additional manipulation before the introduction (heating in a water bath to dissolve the sediment that occurs during storage of the drug below 15° (C)significant material and labor costs, excessive trauma to the animals.

The technical problem solved by this invention is to expand the range of tools and methods for the treatment of mastitis and endometritis in cows.

The essence of the invention lies in the fact that the drug for the prevention and treatment of mastitis cows contains 1,4-di-T-oxide, 2,3-bis-(oxymethyl) cinoxacin, 1,2 propandiol, dimethyl sulfoxide, methyl ester of para-oksibenzoynoy acid, distilled water and according to the invention, these substances are contained in the following ratio of components is having g/%:

1,4-di-N-oxide, 2,3-bis-(oxymethyl) cinoxacin1,0-1,2
traceson3,0-3,18
the sulfoxide10,0-10,5
1,2 propandiol20,0-25
distilled waterrest

Dioxidine (1,4-Di-N-oxide, 2,3-bis-(oxymethyl) finokalia) - greenish-yellow crystalline powder, odorless, slightly in water, alcohol, pH of 1% solution of 5.2 to 7.2. Refers to antimicrobial agents of broad-spectrum. Effective against gram-positive and gram-negative microorganisms. There are strains of bacteria that are resistant to other chemotherapeutic means, including antibiotics. Registered in the Russian Federation (per. ID No. 76/647/1).

Tricresol (krezacin, articlesarticles /2-oxyethyl/ ammonium-ammonium salt articlesarticles acid) is a crystalline powder with a yellowish, creamy or grayish tint, it is soluble in water, has a specific smell, non-toxic. Krezacin activates the pituitary-adrenal system, stimulates the synthesis of protein, activates the ATPase. Stimulates the humoral response, affects the production of cytokines, erythropoiesis, functional properties of hematopoietic stem CL is current, induces production of interferon, reduces the amount of circulating immune complexes, increases in serum Ig g is Used in livestock as a feed additive as a stimulator of the immune system, growth processes, reproductive functions, dairy, meat and egg productivity. After application of the drug products being used without restrictions. Registered in the Russian Federation (Per. No. 10.07.173. - 94 owfp).

Dimethyl sulfoxide is a colorless transparent liquid or colorless crystals (melting at +18,5°C.) with a specific smell. Hygroscopic. Mixed in all respects with water and alcohol. It has the ability to penetrate cell membranes, including through the skin barrier. Possesses analgesic and protivovospalitelnym, mild antiseptic and anti-fibrinolytic action. Enhances skin penetration of certain drugs. Registered in the Russian Federation (per. ID No. 75/244/9).

Propylenglycol (1,2-propandiol) is a colourless, viscous, odorless liquid with a sweet taste. Miscible with water and alcohol in all proportions. Used as a plasticizer and solvent molecular compounds. In veterinary medicine it is used as the solvent and the prolongator medicines.

The essence of the image is etenia also lies in the fact, in a known method of treatment, comprising internatinale the introduction of the drug, according to the invention, the sick animals injected the drug in the teats of the udder at a dose of 10 ml for three to four days, with an interval of 24 hours.

The invention consists also in the fact that in the known method of treatment, including intrauterine administration of the drug, according to the invention, the sick animals injected the drug into the uterine cavity at a dose of 70-100 ml once a day for 4-5 days, with an interval of 24 hours.

A study of the pharmacokinetic properties established that the intrauterine and interculturalism the introduction of the drug is not qualiwed and completely excreted from the body in 24-36 hours. Milk can be used in food 24 hours after the last injection of the drug.

According to the results of Toxicological studies of the drug has low toxicity to animals, has no adverse effects on hematological indices in the recommended routes of administration. LD50gendicine for white mice, intraperitoneal administration is 47.5 ml/kg of body weight. Does not cause chronic toxicity in albino rats and cows.

Has no sensitizing effect, does not randriamaro actions on the conjunctiva, the mucous membrane of the vagina, endometrium and udder parenchyma.

The drug is of antimicrob the e activity against gram-positive and grammaticalising microflora and their various associations, released by mastitis and endometritis. The drug has a uterotonic effect and accelerates the excretion of inflammatory exudate from the uterus.

therapeutic efficacy of the drug during the postnatal purulent-catarrhal endometritis cows is 94,44%. The drug improves the overall resistance of the organism: the increase of hemoglobin (14,49%), albumin (21,18%), level of phagocytic activity of neutrophils (15,55%), lysozyme activity of the serum crazy (36,47%). The drug helps to reduce the service period on average 19-20 days, increase the number of cows, oplodotvoreniya after the first insemination on average by 29%.

The cost of drug treatment is significantly lower than when using other medicines.

therapeutic effect of drugs in serous and subclinical mastitis is 100%, serous, catarrhal - 89,44%. The effectiveness of the treatment of various forms of mastitis specified drug compared to traditional increases on average by 2-12,5%.

Drug use is not accompanied by the development of side effects and complications.

The drug is easy to use, does not require special preparation before the introduction. The drug can be used in the treatment of endometritis and mast is the cows.

The use of the drug and the specified method of treatment reduces the risk of local manifestations of a dysbacteriosis.

The drug is prepared videosjenny way in aseptic conditions, in a specially equipped room. In the container is poured 1,2 propandiol in the number 20,0-25,0 g/%, dimethylsulfoxide - 10,0-10,5 g/%. Heat up 75-82°download dioxidine 1,0-1,2 g/%, stirred until dissolved, add 1/2 of the required amount of distilled water, mix. Then make tricresol (krezacin) 3,0-3,18 g/%, mix until dissolved and the volume was adjusted with distilled water.

Finished dosage form of the drug is a light yellow transparent solution with a pH of 6.5-7.5. Available in glass vials under a breaking capacity of 10 ml, 100 ml, 400 ml

In zavisimosti from the disease the drug is used by interestearning or intrauterine route of administration. In postpartum purulent-catarrhal endometritis drug is injected into the uterine cavity at a dose of 70-100 ml once a day for 4-5 days, with an interval of 24 hours.

Mastitis the drug is administered after careful divania secret from the affected lobe and disinfection of the teat. Administered in the dose of 10 ml once a day for three to four days, with an interval of 24 hours.

Example 1. Study of the effectiveness of the drug PR is postpartum purulent-catarrhal endometritis cows spent in one of the farms of the Novosibirsk region. Infected cows were divided into experimental and control groups of 36 and 20 cows. Animals of the experimental group intrauterine injected drug in a dose of 100 ml once a day for 4-5 days. The composition of the drug following, g/%: 1,4-di-N-oxide, 2,3-bis-(oxymethyl) cinoxacin - 1,0-1,2; tricresol (krezacin) 3,0 - 3,18; sulfoxide - 10,0-10,5; 1,2 propandiol - 20-25; distilled water the rest.

Animals of the control group was used foramen according to the instruction on its use. Before treatment and after five days of experience in 5 animals from the control and experimental groups took blood samples and vaginal mucus for laboratory research.

Comparative therapeutic efficacy against prototype (1% solution dioksidina) was performed according to the main indicators, as reflected in table 3.

It was found that the endometritis mainly observed in cows for 7-10 days after calving and is manifested in the form of abundant uterine-vaginal secretions of grayish-white color mixed with pus, in some cases, the allocation of purchase brownish color. By rectal examination horns of the uterus is enlarged, fluctuant, retraction lowered.

Microbiological analysis of the uterine-vaginal exudate was allocated mainly streptococci (66,11%), diplococci (41,67%) and staphylococci (33,33). Less - culture of Escherichia (19,44%), Proteus (13,89%), Bacillus subtillis (19,44%),Yersinia (16,67%).

they vaginal secretions of cows, patients with postpartum endometritis, leukocyte type, in the field of view destructionand and normal neutrophils, significant accumulations of microbes, there are erythrocytes, isolated epithelial cells.

After the drug clinical picture of the disease was changed the next day, 34 cows from the experimental group and was characterized by a sharp increase in the number of allocated lohii. After the second injection of the drug they produced in much smaller quantities, became transparent and viscous. 3-4 days of treatment uterine-vaginal discharge was absent or stood in small quantities. In they discharge on the second day after treatment decreased the number destructively neutrophils and focal accumulations of microflora, increased the number of epithelial cells. On the fifth day after treatment, they were characterized by isolated clusters of microbes, the advent of simpleton orogovevshih and non-squamous (superficially) epithelial cells and leukocytes.

In controlnow group similar changes in the clinic was observed in 17 cows. Three animals were observed relapses of the disease on the third day after treatment. In they utero-vaginal mucus five days after the treatment preobladayuschii without signs of degeneration, met epithelial superficially cells, accumulation of microbes isolated erythrocytes.

Comparative effectiveness of treatment in relation to known methods (foramen) is presented in table 1.

Table 1
№p/pIndexGroup
experiencedcontrol
goals%goals%
1.Number of goals in the group3620
2.Recovered cows in group3494,441785
3.Were fertilized cows,%3088,23952,94
4.Were fertilized cows after the first insemination, %2264,7635,29
5.The duration of infertility, days64,62±8,2484,33±9,15
6.Index fertilization1,56 2,33
7.Cull cows (animals): all of them:

infertility

abortion

pathology of musculoskeletal system


4

1

2

1


6

4

2

Morphological and biochemical blood parameters of cows experimental and control groups were within physiological norms (table 2).

After drug treatment in cows showed a significant increase in hemoglobin (14,49%), albumin (21,18%), level of phagocytic activity of neutrophils (15,55%) and lysozyme activity of blood serum (36,47%). At the same time in the blood serum of cows in this group decreased content α-globulin (18,55%), γ-globulin (20,53%). The level of bactericidal activity of blood serum did not change (table 2).

In controlnow group of cows the amount of hemoglobin increased by a total of 8.74%, albumin 4.5%. Increased levels of bactericidal and lysozyme activity was unreliable. In the control group of animals decreased the content of total protein (8,92%), α-globulin (by 6.31%), γ-globulin (4.09 to%).

tr>
Table 2
IndexGroup
experiencedControl
Hemoglobin, g / l**
Erythrocytes, 1012l
Leukocytes, 109l
Total protein, g / l**
Calcium, mg/%
The inorganic phosphorus, mg/%
Alkaline reserve, mg/%
Carotene, mg/%
Vitamin E, mg/%
Albumin, %
Alpha-globulins, %
Beta-globulins, %
Gamma-globulins, %
The authors estimated the effect activity of blood serum. %
Bactericidal activity of blood serum, %
Phagocytic activity, %
*P<0,05, **P<0,01

The application of this method of treatment promotes recovery of animals in 94% of cases. Along with this reduced the number of days of infertility (mean 20 days), increases the fertility of cows from the first insemination 1.8 times in comparison with the indices in cows of the control group.

The drug has no adverse effects on hematological indices, increases hemoglobin, total protein, and to increase gozitano activity of neutrophils and lysozyme activity of serum.

Table 3 presents summary data on therapeutic efficacy of the proposed drug and treatment method, a known method of treatment (foramen) and the prototype.

Table 3
№p/pIndexGroup
medicationthe placeholder
experiencedcontrol
1.Number of goals in the group362022
2.Clinically recovered cows in the group %94,448597,46
3.Were fertilized cows, %88,2352,9483,33
4.The duration of infertility, days64,62±8,2484,33±9,1584,3±8,0
5.Index fertilization1,562,331,7

The data indicate that use of the drug can increase the number of fertilized cows in comparison with the prototype 5.36%, reduce the number of days of infertility on 30,46% (19 days) and to improve the index fertilization of 8.97%.

Por what measures 2. Research conducted in the households of the Novosibirsk region. Therapeutic efficacy was determined on the sick cows with diagnoses: serous, serous, catarrhal, subclinical form of mastitis. Animals were formed into six groups (3 test, 3 control). Cows experimental groups in the number 39 was treated with gendicine, which was inserted in the nipple channel by means of a catheter or through a cannula glass syringe after preliminary disinfection nipple once daily at a dose of 10 ml of the drug following, g/%: 1,4-di-N-oxide, 2,3-bis-(oxymethyl) cinoxacin - 1,0-1,2; tricresol (krezacin) - 3,0 - 3,18; sulfoxide - 10,0-10,5; 1,2 propandiol - 20-25; distilled water - the rest.

Cows of the control groups in the number 33 was used vnutriserdechne introduction of antibacterial drugs (masterid, mastison And, mastison E).

Comparative therapeutic efficacy against prototype (1% solution dioksidina) was performed according to the main indicators, as reflected in table 6.

To assess the effectiveness of treatment clinical examination took into account the results of laboratory tests of samples of milk (bacteriological examination, the reaction with 10% solution of masticina, test assertion), duration of treatment, cost of medicines, the concentrations of drug, who is one of the complications the number of recovered animals. The results of the experiments are presented in table 4.

Table 4
IndexForms of mastitis
SerousSerous, catarrhalSubclinical
experiencedcontrolexperiencedcontrolexperiencedcontrol
The number of cows9815101515
Patients share9819131817
Recovered cows971381514
Cured shares9717111816
The lack of therapeutic effect1221
Disease recurrence1- -
The duration of treatment (days)3,43,33,683,692,62,75
The treatment efficiency (%)10087,589,4484,6110098

The results of the analysis of blood serum of patients with serous mastitis cows (table 5), indicate compliance with morphological and biochemical parameters in cows experimental and control groups physiological norm.

Table 5
IndexGroup
experiencedcontrol
Hemoglobin, g / l
Erythrocytes, 1012l
Leukocytes, 109l
Total protein, g / l
Calcium, mg/%
The inorganic phosphorus, mg/%
Alkaline reserve, mg/%
Carotene, mg/%
Vitamin E, mg/%
Albumin, %
Alpha-globulins, %
Beta-globulins, %
Gamma-globulins. %
Alat
AST
Urea
*P<0,05, **P<0,01

Studies have shown that in the blood serum of cows from the experimental group after treatment significantly decreased the activity of enzymes (Alat, ASAT). The reduction of these parameters indicates that the normalization of the indicators of the functional state of the liver and the absence of cytolytic action of the drug on the hepatocytes.

Therapeutic efficacy in the treatment of drug serous and subclinical mastitis was 100%, serous, catarrhal 89,44%. In the control group scores were significantly lower and amounted to: in the treatment of subclinical mastitis 98%, serous, catarrhal 84,61%, serous to 87.5%. The effectiveness of the treatment of various forms of mastitis in the experimental group increased by an average of 2-12,5%.

The drug showed a higher therapeutic efficacy compared to the prototype (table 6). Duration of drug treatment, an average of 1.15 times as long, and therapeutic efficacy, depending on the form of mastitis, an increase of 2.91 in-10,75%.

Thus, the proposed drug and the treatment of mastitis and endometritis in cows is more effective than known.

The technical result to be solved by the invention is to improve the form preparada, which requires no additional manipulation before the introduction (heating up to 40°C)reducing the multiplicity of the introduction and speed up recovery time, increase the effectiveness of treatment.

Table 6
IndexForms of mastitis
SerousSerous, catarrhalSubclinical
experiencedcontrolthe placeholderexperiencedcontrolthe placeholderexperiencedcontrolthe placeholder
The number of cows98915108151510
Patients share981019138181710
Recovered cows978138715147
Cured shares97917 11718167
The lack of therapeutic effect112213
Disease recurrence11--1
The duration of treatment (days)3,43,34,03,683,694.26 deaths2,62,753,2
The treatment efficiency (%)10087,589,2589,4484,6186,531009896,22

1. Drug for the treatment of postpartum purulent-catarrhal endometritis, serous, serous, catarrhal and subclinical mastitis in cows, including 1,4-di-N-oxide, 2,3-bis-(oxymethyl) cinoxacin and water, characterized in that it further includes tricresol, dimethylsulfoxide and 1,2 propandiol in the following ratio of components, g/%:

1,4-di-N-Ocis,3-bis-(oxymethyl) cinoxacinTricresol (krezacin)3,0-3,18
The sulfoxide10,0-10,5
1,2 propandiol20-25
Distilled waterRest

2. The method of treatment of postpartum purulent-catarrhal endometritis, serous, serous, catarrhal and subclinical mastitis in cows, including the introduction of a drug, wherein the drug is administered according to claim 1 once a day for 3-5 days.

3. The method according to claim 2, characterized in that for the treatment of postpartum purulent-catarrhal endometritis drug is injected into the uterine cavity at a dose of 70-100 ml

4. The method according to claim 2, characterized in that for the treatment of serous, serous, catarrhal and subclinical mastitis the drug is administered internatinale in the affected part of the udder at a dose of 10 ml



 

Same patents:

FIELD: organic chemistry, amino acids.

SUBSTANCE: invention proposes the novel derivatives of phenylalanine of the formula (I) and (II) possessing with antagonistic activity with respect to α4-integrin. Derivatives of phenylalanine are used as therapeutic agents in different diseases associated with α4-integrin.

EFFECT: valuable medicinal properties of compounds.

37 cl, 30 tbl, 215 ex

FIELD: organic chemistry, chemical technology, pharmacy.

SUBSTANCE: invention relates to novel O-substituted derivatives of 6-methyltramadol of the general formula (I) being optionally as their racemates, their pure stereoisomers but primarily as enantiomers or diastereomers, or as mixtures of stereomers being primarily as enantiomers or disatereomers in any their ratio in the mixture as a presented formulation or as their physiologically compatible salts. In the general formula (I) the value R means hydrogen atom (H), (C1-C3)-alkyl that can be saturated or unsaturated, branched or a direct, unsubstituted or substituted with -O-(C1-C3)-alkyl-group or OH-group, -CH2-(C4-C6)-cycloalkyl, (C4-C6)-cycloalkyl or thienyl group. Also, the invention relates to a method for synthesis of compounds of the general formula (I) by interaction of 2-dimethylaminomethyl-6-methylcyclohexanone of the formula (I) with metal-organic compound of the formula (III) wherein Z means Li; R has values given in the formula (I). The synthesized compounds of the formula (I) if necessary are converted to their physiologically compatible salts and/or racemates that are subjected for cleaving. Also, invention relates to a pharmaceutical composition.

EFFECT: improve method of synthesis, valuable medicinal properties of compounds and pharmaceutical composition.

8 cl, 2 sch, 2 tbl, 30 ex

FIELD: chemical-pharmaceutical industry, medicine, peptides.

SUBSTANCE: invention relates to preparing and using peptides of the formula (I) possessing analgesic activity: A-B-Tyr-Pro(D-Pro, dHPro, D-dHPro, DL-dHPro, Hyp)-C-X wherein A means -O, -Ala, -Asp, -Glu, -Phe, -Gly, -His, -He, -Lys, -Leu, -Met, -Pro, -Arg, -Ser, -Thr, -Val, -Trp, -Tyr; B means 0, -Ala, -Asp, -Glu, -Phe, -Gly, -His, -He, -Lys, -leu, -Met, -Pro, -Arg, -Ser, -Thr, -Val, -Trp, -Tyr; C means 0, -Ala, -Asp, -Glu, -Phe, -Gly, -His, -He, -Lys, -Leu, -Met, -Pro, -Arg, -Ser, -Thr, -Val, -Trp, -Tyr; X means -OH, -OCH3, -NH2. Proposed peptides can be used for design of new medicinal preparations. Peptides possess the enhanced activity as compared with pentalgin, analgin and morphine and have no toxic properties.

EFFECT: improved and valuable medicinal properties of peptides.

5 tbl, 4 ex

FIELD: pharmaceutical industry, in particular analgesic, vasodilatation, anti-inflammation ointment for topical application.

SUBSTANCE: claimed ointment is prepared in form of fine dispersed formulation containing bee venom extract melittin, lavender oil, camphor, arnica tincture, rosemary oil, eucalyptus oil, revitalin, carbopol, 30 % solution of sodium hydroxide, hydrophilic anionic ointment, soy lecithin, glycerol, conserving solution, ethanol, distilled water.

EFFECT: reduced toxicity of bee venom, decreased side effects and improved therapeutic effect.

2 tbl, 3 ex

FIELD: organic chemistry, medicine, veterinary science, pharmacy.

SUBSTANCE: invention relates to derivatives of tetrahydropyranyl-cyclopentyl-tetrahydropyridopyridine of the formula (1): , wherein R3 means oxygen atom or absent; R8 is chosen from: (a) hydrogen atom; (b) (C1-C3)-alkyl that can be unsubstituted or substituted with 1-6 fluorine atoms; (c) -O-(C1-C3)-alkyl; (d) fluorine atom, and (e) hydroxy-group, and their pharmaceutically acceptable salts and separate diastereomers. These compounds are modulators of activity of chemokine receptors. Also, invention relates to a pharmaceutical composition based on compounds of the formula (1), method for modulation of activity of chemokine receptors in humans and animals and a method for preparing a medicinal agent. Invention provides preparing novel modulators of chemokine receptors activity.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

8 cl, 13 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of 2-phenylaminoimidazoline phenylketone that can be used as IP antagonists. Invention describes 2-phenylaminoimidazoline phenylketone of the general formula (I): wherein R1 mean optionally substituted aryl wherein R1 is optionally substituted with 1, 2 or 3 substitutes chosen independently from series including alkoxy-group, aryl aryloxy-, aralkyloxy-group, halogen atom, ethylenedioxy-group or optionally substituted heterocyclyl that means a monovalent saturated carbocyclic radical comprising from 3 to 7 atoms in cycle and comprising one or two heteroatoms chosen independently from nitrogen and oxygen atoms, and can be optionally substituted with one or more substitutes chosen independently from alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkyl sulfonyl, furanyloxy-group; R2 means hydrogen atom; A means -C(O)-(CH2)n- or -C(O)-CH2-O-; index n means a whole number from 2 to 6, or its pharmaceutically acceptable salt or solvate. Invention provides preparing novel compounds showing useful biological properties.

EFFECT: valuable properties of compounds.

16 cl, 1 tbl, 23 ex

FIELD: pharmaceutical industry, in particular cyprofloxacine solution.

SUBSTANCE: claimed solution contains cyprofloxacine hydrochloride, sodium salt of ethylenediamine-N,N,N1,N1-tetraacetic acid, α-hydroxypropionic acid, sodium chloride, water for injections.

EFFECT: drug of increased biological availability without side effects.

3 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of amide of the general formula (I)

wherein X means -CH; Y means -CH or nitrogen atom (N); m = 1 or 2; R1 means (C1-C6)-alkyl, (C1-C)-alkoxy-group, N,N-di-[(C1-C6)-alkyl]-amino-group, heterocyclyl-(C1-C6)-alkyl wherein heterocyclyl represents piperazinyl or homopiperazinyl; n = 3; R2 means halogen atom, (C1-C6)-alkyl; R3 means hydrogen atom; Q means phenyl optionally substituted with cyano-group, or pyridyl optionally substituted with morpholino-group, or their pharmaceutically acceptable salts, to methods for synthesis of indicated compounds, pharmaceutical compositions containing thereof and their using in treatment of diseases or states mediated by cytokines.

EFFECT: improved preparing methods, valuable medicinal properties of compounds and pharmaceutical compositions.

10 cl, 2 tbl, 7 ex

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to a method for preparing modified glycosaminoglycans possessing analgesic properties. Method involves interaction of glycosaminoglycans with 1-phenyl-2,3-dimethyl-4-aminopyrazolone-5-(4-aminoantipyrine) in aqueous medium at pH = 4.7-4.8 in the presence water-soluble 1-ethyl-3-[3-(dimethlamino)propyl]carbodiimide as a condensing agent at room temperature followed by purification from low-molecular reagents. Method involves a single step that simplifies technology in preparing modified glycosaminoglycans.

EFFECT: improved preparing method.

3 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to inhibitor of matrix metalloproteinases representing extract from fungus Canoderma atrum obtained by using of water and/or lower alcohols as extractant. Also disclosed are pharmaceutical agent for inhibition of tumor metastasis containing of 0.03-10 wt.% of abovementioned extract and foodstuff containing claimed extract.

EFFECT: improved inhibitor of matrix proteinases.

3 cl, 18 ex, 4 tbl

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to new derivatives of pyrrolopyrimidine of the formula (1) and their pharmaceutically acceptable salts possessing properties of selective inhibitor of specific cyclic guanosine 3',5'-monophosphate phosphodiesterase (specific cGMP PDE) (PDE V). In the formula (1) R1 represents hydrogen atom (H), (C1-C3)-alkyl substituted optionally with one or some fluorine atoms; R2 represents H, halogen atom, (C1-C6)-alkyl substituted optionally with hydroxyl group (-OH), (C1-C3)-alkoxy-group, (C3-C6)-cycloalkyl or one or some fluorine atoms, (C3-C6)-cycloalkyl; R3 represents (C1-C6)-alkyl substituted optionally with (C3-C6)-cycloalkyl or one or some fluorine atoms; R4 represents (C1-C6)-alkyl substituted optionally with one or some fluorine atoms; R5 represents -SO2NR6R, -NHSO2R8 or heterocyclyl such as tetrazolyl; each R6 and R7 represents independently H or (C1-C6)-alkyl substituted optionally with -CO2H or one or some fluorine atoms; or in common with nitrogen atom to which they are bound form monocylic ring, such as imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine wherein indicated group is replaced optionally with R9 wherein R9 represents (C1-C6)-alkyl substituted optionally with one or some halogen atoms, hydroxyl group (OH), (C1-C3)-alkoxy-group that is replaced optionally with one or some fluorine atoms, -NR11R12, -C=NR13(NR14R15) or tetrazolyl group, 6-membered nitrogen-containing heteroaryl group; each R11 and R12 represents independently H or (C1-C4)-alkyl; R13represents H; each R14 and R15 represents independently H. Also, invention relates to intermediate compounds, methods for preparing compounds and pharmaceutical compositions. Proposed compounds can be used in treatment of impotency, sexual dysfunction in females, stable, nonstable and variant (Prinzmental) stenocardia and other diseases also.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

15 cl, 1 tbl, 250 ex

FIELD: veterinary science.

SUBSTANCE: one should apply liniment that contains an active substance being "Todicamp-ideal" and a vegetable foundation as a mustard-pumpkin fuse obtained while manufacturing "Volgogradskoe" vegetable oil at weight ratio of mustard and pumpkin oils being 1:9 weight portions. Moreover, "Todicamp-ideal" and mustard-pumpkin fuse are at weight ratio of 10-12 : 90-88 weight portions. In some cases of liniment application upon affected part of cow's udder should be combined with peroral intake of "Todicamp-ideal". The innovation provides simultaneous antiphlogistic, antimicrobial and immunostimulating effect.

EFFECT: higher efficiency of therapy.

2 cl, 2 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: medicine; physiotherapy; urology.

SUBSTANCE: method can be used for complex treatment of patients suffering from erectile prostatitis complicated with symptoms of erectile dysfunction. Perineum is subject to SMC-therapy proserin electrophoresis simultaneously with pulse magnetic field. Combined effect is performed within 2 steps. At first step, SMC-therapy proserin electrophoresis at perineum is performed at rectified mode of SMC-I (constant modulation) sort of operation at modulation frequency of 20-30 Hz, depth of modulation of 75-100%, current strength of 20-30 mA and duration of influence of 5-7 minutes. Simultaneously perineum area is subject to rectangular pulse magnetic field during 5-7 minutes. Frequency of rectangular pulse magnetic field equals to 20-30 Hz, magnetic induction is equal to 20-30 tesla. At second step the effect of proserin electrophoresis is performed at rectified mode IV (permanent frequency) of operation with modulation frequency of 20-30 Hz., depth of modulation of 100% and higher, duration of sendings 4s:6s and bipolar rectangular pulse magnetic field is used for influence during 8-10 minutes. Frequency of bipolar rectangular pulse magnetic field equals to 20-30 Hz. Longer period of remission is observed due to usage of combined influence of proserin electrophoresis and magnetic field at mentioned modes of operation.

EFFECT: improved electrophoresis permeability of cutaneous coverings; increased efficient concentration of proserin in prostate.

4 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out vacuum massage of prostate with an apparatus. Tampons with 40-45°C hot sulfide mud taken from Sucsun pond are additionally rectally introduced for 20-30 min. The total treatment course is 8-10 procedures long. Daily microenemas are prescribed with mineral water at 36°C in a 10 procedures long course.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine, gynecology.

SUBSTANCE: during the first half of the day it is necessary to dissolve 10 mg cortexin and 4 mg nicergolin in10 ml of novocain solution or physiological solution, then this quantity of solution should be divided into 10 portions to be injected paravertebrally for the depth of about 0.7-1.0 cm in projection of C4-C7 segments. Duration of therapy corresponds to 10 d. The innovation provides modulation of metabolism of neuromediators and antioxidant systems in combination with activation of cerebral neurotrophic processes and, as a result, normalization of neuro-autonomic symptomatics for 6 mo that enables to apply it as alternative of hormonal therapy in case of climacteric syndrome.

EFFECT: higher efficiency of therapy.

2 ex, 2 tbl

FIELD: medicine, gynecology.

SUBSTANCE: during the first half of the day it is necessary to dissolve 10 mg cortexin and 4 mg nicergolin in10 ml of novocain solution or physiological solution, then this quantity of solution should be divided into 10 portions to be injected paravertebrally for the depth of about 0.7-1.0 cm in projection of C4-C7 segments. Duration of therapy corresponds to 10 d. The innovation provides modulation of metabolism of neuromediators and antioxidant systems in combination with activation of cerebral neurotrophic processes and, as a result, normalization of neuro-autonomic symptomatics for 6 mo that enables to apply it as alternative of hormonal therapy in case of climacteric syndrome.

EFFECT: higher efficiency of therapy.

2 ex, 2 tbl

FIELD: medicine, gynecology.

SUBSTANCE: before operation it is necessary to sample patient's blood to divide it into plasma and blood cells. Blood plasma should be divided into three parts and frozen. After operation one should intravenously reinfuse by drops erythrocytic mass incubated for 30 min at 37° C with 2 g lendacyn followed by further lendacyn injection per 1g intramuscularly during the next 6 d. Blood plasma should be portionally defrosted, incubated at 37° C with: 10000 U trasilol, 0.15 g lisozyme, 0.02 g novocain, after incubation it is necessary to add 100 ml gelatinol to be reinfused for a patient on the 2nd, 4th and 6th d against the onset of therapy course through microirrigator withdrawn out of posterior arch during operation. The innovation provides combined impact of antibiotics upon pathological focus biotransformed with erythrocytic mass and local immunomodulating and resolving effect and, thus, decreased formation of adhesions, fistulas and cicatrices.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel amino- and hydroxy-derivatives of phenyl-3-aminomethylquinolone-2 of the general formula (1):

wherein R1, R2, R3 and R4 are independently similar or different and R1 is chosen from hydrogen atom (H), Alk, OAlk; R2 is chosen from H, Alk, OAlk, -OCF3; R3 is chosen from H, Alk, OAlk, -SCH3; R4 is chosen from H. Alk, OAlk, or R2 and R3 are chosen from -(CH2)3, -OCH2O-, -OCH2CH2O-; R5 means H or Alk; R6, R7 and R9 mean H; R8 is chosen independently from the following substitutes:

wherein n = 1, 2, 3; Het represents furan; R represents hydrogen atom or alkyl. In case of hydroxy-derivatives at least one among R6, R7, R8 or R9 is -OH and other represent H. Also, invention relates to methods for synthesis of these compounds and to a pharmaceutical composition based on these compounds inhibiting activity of NO-synthase. Invention provides preparing novel compounds and pharmaceutical compositions based on thereof in aims for treatment of diseases associated with hyperactivity of phagocytizing cells, for example, rheumatic arthritis, asthma and others.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of compounds and pharmaceutical composition.

32 cl, 1 tbl, 132 ex

FIELD: medicine.

SUBSTANCE: method involves determining lymphocyte CD 56+ in peripheral blood before planned pregnancy. The content exceeding norm, lymphocytoimmunotherapy courses are applied with donor lymphocytes. The courses are applied at the fifth-eighth day of fertility cycle until normal lymphocyte CD 56+ values become restored. Pregnancy being proved, lymphocytoimmunotherapy courses are applied with ultrasonic examination results having in view. Choriohypoplasia being available, the courses are applied every 2 weeks. Chorion thickness being in conformity with gestation age, the courses are applied every 3-4 weeks to 12-14 pregnancy weeks.

EFFECT: adequate chorion and placenta development.

2 tbl

Up!